High-resolution Epitope Mapping and Characterization of SARS-CoV-2 Antibodies in Large Cohorts of Subjects with COVID-19

Overview

Journal Commun Biol

Specialty Biology

Date 2021 Nov 23

PMID 34811480

Citations 26

Authors

Winston A Haynes

Kathy Kamath

Joel Bozekowski

Elisabeth Baum-Jones

Melissa Campbell

Arnau Casanovas-Massana

Patrick S Daugherty

Charles S Dela Cruz

Abhilash Dhal

Shelli F Farhadian

Lynn Fitzgibbons

John Fournier

Michael Jhatro

Gregory Jordan

Jon Klein

Carolina Lucas

Debra Kessler

Larry L Luchsinger

Brian Martinez

M Catherine Muenker

Lauren Pischel

Jack Reifert

Jaymie R Sawyer

Rebecca Waitz

Elsio A Wunder Jr

Minlu Zhang

Akiko Iwasaki

Albert Ko

John C Shon

Affiliations

Soon will be listed here.

Abstract

As Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to spread, characterization of its antibody epitopes, emerging strains, related coronaviruses, and even the human proteome in naturally infected patients can guide the development of effective vaccines and therapies. Since traditional epitope identification tools are dependent upon pre-defined peptide sequences, they are not readily adaptable to diverse viral proteomes. The Serum Epitope Repertoire Analysis (SERA) platform leverages a high diversity random bacterial display library to identify proteome-independent epitope binding specificities which are then analyzed in the context of organisms of interest. When evaluating immune response in the context of SARS-CoV-2, we identify dominant epitope regions and motifs which demonstrate potential to classify mild from severe disease and relate to neutralization activity. We highlight SARS-CoV-2 epitopes that are cross-reactive with other coronaviruses and demonstrate decreased epitope signal for mutant SARS-CoV-2 strains. Collectively, the evolution of SARS-CoV-2 mutants towards reduced antibody response highlight the importance of data-driven development of the vaccines and therapies to treat COVID-19.

Citing Articles

Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting.

Seow J, Jefferson G, Keegan M, Yau Y, Snell L, Doores K PLoS Pathog. 2024; 20(11):e1012724.

PMID: 39556615 PMC: 11611254. DOI: 10.1371/journal.ppat.1012724.

Differential patterns of antibody response against SARS-CoV-2 nucleocapsid epitopes detected in sera from patients in the acute phase of COVID-19, convalescents, and pre-pandemic individuals.

Razim A, Pacyga-Prus K, Kazana-Pluszka W, Zablocka A, Macala J, Cieplucha H Pathog Dis. 2024; 82.

PMID: 39354682 PMC: 11556334. DOI: 10.1093/femspd/ftae025.

Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein.

Lechuga G, Temerozo J, Napoleao-Pego P, Carvalho J, Gomes L, Bou-Habib D Int J Mol Sci. 2024; 25(15).

PMID: 39125749 PMC: 11311977. DOI: 10.3390/ijms25158180.

Performance evaluation of microfluidic microplate-based fluorescent ELISA for qualitative detection of SARS-CoV-2-specific IgG and IgM.

Kweon O, Yoon S, Choe K, Kim H, Lim Y, Lee M Sci Rep. 2024; 14(1):18200.

PMID: 39107336 PMC: 11303516. DOI: 10.1038/s41598-024-67977-9.

Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters.

Girard B, Baum-Jones E, Best R, Campbell T, Coupart J, Dangerfield K Front Immunol. 2024; 15:1285278.

PMID: 38562934 PMC: 10983613. DOI: 10.3389/fimmu.2024.1285278.

References

Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D . Covid-19 and autoimmunity. Autoimmun Rev. 2020; 19(8):102597. PMC: 7289100. DOI: 10.1016/j.autrev.2020.102597. View

Edridge A, Kaczorowska J, Hoste A, Bakker M, Klein M, Loens K . Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020; 26(11):1691-1693. DOI: 10.1038/s41591-020-1083-1. View

Anand P, Puranik A, Aravamudan M, Venkatakrishnan A, Soundararajan V . SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. Elife. 2020; 9. PMC: 7343387. DOI: 10.7554/eLife.58603. View

Elbe S, Buckland-Merrett G . Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall. 2019; 1(1):33-46. PMC: 6607375. DOI: 10.1002/gch2.1018. View

Yurkovetskiy L, Wang X, Pascal K, Tomkins-Tinch C, Nyalile T, Wang Y . Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. Cell. 2020; 183(3):739-751.e8. PMC: 7492024. DOI: 10.1016/j.cell.2020.09.032. View

Ibarrondo F, Fulcher J, Goodman-Meza D, Elliott J, Hofmann C, Hausner M . Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med. 2020; 383(11):1085-1087. PMC: 7397184. DOI: 10.1056/NEJMc2025179. View

Hansen J, Baum A, Pascal K, Russo V, Giordano S, Wloga E . Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020; 369(6506):1010-1014. PMC: 7299284. DOI: 10.1126/science.abd0827. View

Amrun S, Lee C, Lee B, Fong S, Young B, Chee R . Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine. 2020; 58:102911. PMC: 7375792. DOI: 10.1016/j.ebiom.2020.102911. View

Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S, Hayashi K . Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020; 94:154-155. PMC: 7270890. DOI: 10.1016/j.ijid.2020.03.020. View

10.

Zhang L, Jackson C, Mou H, Ojha A, Peng H, Quinlan B . SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020; 11(1):6013. PMC: 7693302. DOI: 10.1038/s41467-020-19808-4. View

11.

Wang L, Shi W, Chappell J, Joyce M, Zhang Y, Kanekiyo M . Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. J Virol. 2018; 92(10). PMC: 5923077. DOI: 10.1128/JVI.02002-17. View

12.

Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View

13.

Fernandez A . Structural Impact of Mutation D614G in SARS-CoV-2 Spike Protein: Enhanced Infectivity and Therapeutic Opportunity. ACS Med Chem Lett. 2020; 11(9):1667-1670. PMC: 7433342. DOI: 10.1021/acsmedchemlett.0c00410. View

14.

Hu W, Howell J, Ozturk T, Benameur K, Bassit L, Ramonell R . Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020. Emerg Infect Dis. 2020; 26(12):2974-2978. PMC: 7706962. DOI: 10.3201/eid2612.203334. View

15.

Johnson B, Xie X, Bailey A, Kalveram B, Lokugamage K, Muruato A . Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021; 591(7849):293-299. PMC: 8175039. DOI: 10.1038/s41586-021-03237-4. View

16.

Zhang L, Zhang F, Yu W, He T, Yu J, Yi C . Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J Med Virol. 2005; 78(1):1-8. PMC: 7166884. DOI: 10.1002/jmv.20499. View

17.

Kreye J, Reincke S, Pruss H . Do cross-reactive antibodies cause neuropathology in COVID-19?. Nat Rev Immunol. 2020; 20(11):645-646. PMC: 7537977. DOI: 10.1038/s41577-020-00458-y. View

18.

Hachim A, Kavian N, Cohen C, Chin A, Chu D, Mok C . ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nat Immunol. 2020; 21(10):1293-1301. DOI: 10.1038/s41590-020-0773-7. View

19.

Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D . Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2):281-292.e6. PMC: 7102599. DOI: 10.1016/j.cell.2020.02.058. View

20.

Poston D, Weisblum Y, Wise H, Templeton K, Jenks S, Hatziioannou T . Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. Clin Infect Dis. 2020; 73(5):e1208-e1211. PMC: 7799301. DOI: 10.1093/cid/ciaa1803. View